microRNA information: hsa-miR-101-3p
Section | ID | link |
---|---|---|
Mature name: | hsa-miR-101-3p | miRbase |
Accession: | MIMAT0000099 | miRbase |
Precursor name: | hsa-mir-101-1 | miRbase |
Precursor accession: | MI0000103 | miRbase |
Symbol: | MIR101-1 | HGNC |
RefSeq ID: | NR_029516 | GenBank |
Sequence: | UACAGUACUGUGAUAACUGAA |
Reported expression in cancers: hsa-miR-101-3p
miRNA | cancer | regulation | reporting | PUBMED | method |
---|---|---|---|---|---|
hsa-miR-101-3p | bladder cancer | downregulation | "Here we report that the expression of microRNA-101 ......" | 23618864 | |
hsa-miR-101-3p | bladder cancer | downregulation | "The microRNA miR-101 is downregulated in several c ......" | 25658842 | |
hsa-miR-101-3p | breast cancer | downregulation | "microRNA-101 miR-101 is down-regulated in several ......" | 25059472 | qPCR |
hsa-miR-101-3p | cervical and endocervical cancer | downregulation | "The profiles of miRNA in cervical cancer and chron ......" | 24528073 | Microarray; qPCR; in situ hybridization |
hsa-miR-101-3p | cervical and endocervical cancer | downregulation | "Previously we found that miR-101 is significantly ......" | 26617722 | |
hsa-miR-101-3p | chronic myeloid leukemia | deregulation | "Some onco-miRNAs were found to be downregulated mi ......" | 25833191 | |
hsa-miR-101-3p | colon cancer | upregulation | "Here we show that miR-101 expression is differenti ......" | 22930392 | |
hsa-miR-101-3p | colorectal cancer | downregulation | "Among the inferred candidates three miRNAs miR-101 ......" | 25286864 | |
hsa-miR-101-3p | colorectal cancer | downregulation | "miR-455 miR-484 and miR-101 were significantly dow ......" | 25355599 | |
hsa-miR-101-3p | esophageal cancer | downregulation | "To investigate the role of miR-101 in the regulati ......" | 25400732 | |
hsa-miR-101-3p | gastric cancer | downregulation | "MicroRNA microarray expression profiling and array ......" | 22450781 | Microarray; qPCR |
hsa-miR-101-3p | gastric cancer | downregulation | "In this study we reported that miR-101 is signific ......" | 25561270 | |
hsa-miR-101-3p | glioblastoma | upregulation | "Quantitative real-time PCR showed that miR-101 exp ......" | 25230316 | qPCR |
hsa-miR-101-3p | head and neck cancer | deregulation | "A global miRNA profiling was performed on 12 sampl ......" | 21637912 | qPCR; Microarray |
hsa-miR-101-3p | liver cancer | downregulation | "miR-101 a significantly down-regulated miRNA was f ......" | 19155302 | |
hsa-miR-101-3p | liver cancer | downregulation | "Moreover the down-regulation of miR-101 in clinica ......" | 23178713 | |
hsa-miR-101-3p | liver cancer | downregulation | "Based on our prior observations that miRNA-101 miR ......" | 24260081 | qPCR |
hsa-miR-101-3p | liver cancer | downregulation | "However the correlation between HBV and miR-101 ha ......" | 24697700 | |
hsa-miR-101-3p | liver cancer | downregulation | "Here we examine how HBV affects the production of ......" | 24788845 | |
hsa-miR-101-3p | lung cancer | downregulation | "miR 101 DNA copy loss is a prominent subtype speci ......" | 21849855 | |
hsa-miR-101-3p | lung cancer | downregulation | "At the same time microRNA-101 mir-101 was found to ......" | 25428391 | |
hsa-miR-101-3p | lung cancer | downregulation | "The deregulation of miR-101 has been implicated in ......" | 26628987 | |
hsa-miR-101-3p | lung squamous cell cancer | downregulation | "MiR-101 has been reported down-regulated in variou ......" | 21993632 | |
hsa-miR-101-3p | lymphoma | downregulation | "Histone deacetylase inhibitor prevents cell growth ......" | 24577510 | Microarray |
hsa-miR-101-3p | melanoma | downregulation | "The microRNA miR-101 has been reported to be a tum ......" | 23962556 | |
hsa-miR-101-3p | pancreatic cancer | upregulation | "miR-101 is an outstanding tumor suppressor in vari ......" | 25968875 | |
hsa-miR-101-3p | prostate cancer | downregulation | "Candidate serum miRNAs were detected by using PCR ......" | 24477576 | Microarray; qPCR |
hsa-miR-101-3p | retinoblastoma | downregulation | "miR-101 has been identified as a tumor suppressor ......" | 24807198 | |
hsa-miR-101-3p | sarcoma | downregulation | "miR-101 is downregulated in various types of cance ......" | 25190211 | |
hsa-miR-101-3p | thyroid cancer | downregulation | "The results showed that miR-101 was significantly ......" | 24649082 | |
hsa-miR-101-3p | thyroid cancer | downregulation | "This study revealed that miR-101 is significantly ......" | 25202416 |
Reported cancer pathway affected by hsa-miR-101-3p
miRNA | cancer | pathway | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-101-3p | bladder cancer | Apoptosis pathway | "Methyl jasmonate sensitizes human bladder cancer c ......" | 24490857 | Flow cytometry |
hsa-miR-101-3p | bladder cancer | Apoptosis pathway | "Enforced expression of miR 101 enhances cisplatin ......" | 25109742 | Western blot; MTT assay; Luciferase |
hsa-miR-101-3p | breast cancer | Apoptosis pathway | "miR 101 promotes breast cancer cell apoptosis by t ......" | 25059472 | MTT assay; Flow cytometry; Western blot |
hsa-miR-101-3p | breast cancer | Apoptosis pathway | "The aim of our study was to investigate the functi ......" | 26036638 | Luciferase |
hsa-miR-101-3p | cervical and endocervical cancer | Apoptosis pathway | "Although aberrant miRNA expression has been docume ......" | 24289600 | Flow cytometry; Wound Healing Assay |
hsa-miR-101-3p | cervical and endocervical cancer | cell cycle pathway | "miR 101 inhibits the G1 to S phase transition of c ......" | 24987920 | Western blot; Luciferase; Flow cytometry |
hsa-miR-101-3p | cervical and endocervical cancer | Apoptosis pathway | "Previously we found that miR-101 is significantly ......" | 26617722 | MTT assay; Flow cytometry |
hsa-miR-101-3p | colon cancer | Epithelial mesenchymal transition pathway | "Loss of miR 101 expression promotes Wnt/β catenin ......" | 22930392 | |
hsa-miR-101-3p | colorectal cancer | cell cycle pathway; Apoptosis pathway | "Effect of miR 101 on biological characteristics of ......" | 27435782 | Colony formation; Flow cytometry |
hsa-miR-101-3p | esophageal cancer | Apoptosis pathway | "miR 101 suppresses tumor proliferation and migrati ......" | 25400732 | Flow cytometry; Wound Healing Assay |
hsa-miR-101-3p | gastric cancer | Apoptosis pathway | "Downregulation of miR 101 in gastric cancer correl ......" | 23013439 | |
hsa-miR-101-3p | gastric cancer | cell cycle pathway | "MiR 101 inhibits cell growth and tumorigenesis of ......" | 25561270 | Colony formation |
hsa-miR-101-3p | glioblastoma | Apoptosis pathway | "miR 101 acts as a tumor suppressor by targeting Kr ......" | 25230316 | Luciferase |
hsa-miR-101-3p | liver cancer | Apoptosis pathway | "miR-101 a significantly down-regulated miRNA was f ......" | 19155302 | Luciferase |
hsa-miR-101-3p | liver cancer | Apoptosis pathway | "miR 101 inhibits autophagy and enhances cisplatin ......" | 23483142 | |
hsa-miR-101-3p | liver cancer | cell cycle pathway | "Further expression analyses using a large panel of ......" | 23544130 | |
hsa-miR-101-3p | liver cancer | cell cycle pathway; Apoptosis pathway | "Oncogene polycomb group protein enhancer of zeste ......" | 24211739 | Luciferase; Colony formation |
hsa-miR-101-3p | liver cancer | Apoptosis pathway | "Functional analysis of miR 101 3p and Rap1b involv ......" | 24697700 | Luciferase |
hsa-miR-101-3p | liver cancer | Epithelial mesenchymal transition pathway | "However the efficacy of miR-101 replacement therap ......" | 25693145 | |
hsa-miR-101-3p | lung cancer | Apoptosis pathway | "miR 101 represses lung cancer by inhibiting intera ......" | 26349988 | |
hsa-miR-101-3p | lung squamous cell cancer | Apoptosis pathway | "In this study we investigate whether miRNA miR-101 ......" | 21270667 | Luciferase |
hsa-miR-101-3p | lymphoma | cell cycle pathway; Apoptosis pathway | "MicroRNA profiles were correlated with correspondi ......" | 21960592 | |
hsa-miR-101-3p | ovarian cancer | Apoptosis pathway | "MicroRNA-101 miR-101 expression is negatively asso ......" | 21818714 | Wound Healing Assay |
hsa-miR-101-3p | prostate cancer | Apoptosis pathway; PI3K/Akt signaling pathway | "RLIP76 dependent suppression of PI3K/AKT/Bcl 2 pat ......" | 26067553 | Flow cytometry; MTT assay |
hsa-miR-101-3p | retinoblastoma | cell cycle pathway; Apoptosis pathway | "MiR 101 downregulated in retinoblastoma functions ......" | 24807198 | |
hsa-miR-101-3p | sarcoma | Apoptosis pathway | "Studies have proved that microRNA-101 miR-101 func ......" | 25480586 |
Reported cancer prognosis affected by hsa-miR-101-3p
miRNA | cancer | prognosis | reporting | PUBMED | functional study |
---|---|---|---|---|---|
hsa-miR-101-3p | bladder cancer | cell migration | "Here we report that the expression of microRNA-101 ......" | 23618864 | |
hsa-miR-101-3p | bladder cancer | cell migration | "miR 101 suppresses vascular endothelial growth fac ......" | 25658842 | Transwell assay; Western blot; Luciferase; Cell Proliferation Assay |
hsa-miR-101-3p | breast cancer | staging | "The aim of our study was to investigate the functi ......" | 26036638 | Luciferase |
hsa-miR-101-3p | breast cancer | progression; staging; metastasis; worse prognosis | "Whereas miR-101 is involved in the development and ......" | 26360780 | |
hsa-miR-101-3p | cervical and endocervical cancer | tumorigenesis; cell migration | "Although aberrant miRNA expression has been docume ......" | 24289600 | Flow cytometry; Wound Healing Assay |
hsa-miR-101-3p | cervical and endocervical cancer | tumorigenesis; motility | "Previously we found that miR-101 is significantly ......" | 26617722 | MTT assay; Flow cytometry |
hsa-miR-101-3p | colon cancer | motility | "MicroRNA 101 miR 101 post transcriptionally regula ......" | 22353936 | Luciferase |
hsa-miR-101-3p | colon cancer | poor survival; malignant trasformation; worse prognosis | "Loss of miR 101 expression promotes Wnt/β catenin ......" | 22930392 | |
hsa-miR-101-3p | colorectal cancer | progression | "Downloading from GEO Gene Expression Omnibus datab ......" | 25755742 | |
hsa-miR-101-3p | colorectal cancer | poor survival | "Two miRNAs infrequently expressed in the populatio ......" | 27517623 | |
hsa-miR-101-3p | esophageal cancer | metastasis | "miR 101 suppresses tumor proliferation and migrati ......" | 25400732 | Flow cytometry; Wound Healing Assay |
hsa-miR-101-3p | esophageal cancer | progression; metastasis | "Cyclooxygenase 2 a Potential Therapeutic Target Is ......" | 26556718 | Flow cytometry; Western blot; Luciferase |
hsa-miR-101-3p | gastric cancer | metastasis | "Downregulation of miR 101 in gastric cancer correl ......" | 23013439 | |
hsa-miR-101-3p | gastric cancer | progression; tumorigenesis | "Expressions of COX 2 PKC α and miR 101 in gastric ......" | 23644120 | Western blot |
hsa-miR-101-3p | gastric cancer | tumorigenesis; progression | "MiR 101 inhibits cell growth and tumorigenesis of ......" | 25561270 | Colony formation |
hsa-miR-101-3p | gastric cancer | cell migration | "miR 101 2 miR 125b 2 and miR 451a act as potential ......" | 26458815 | Western blot; Colony formation |
hsa-miR-101-3p | gastric cancer | progression; worse prognosis | "Long non coding RNA XIST regulates gastric cancer ......" | 27620004 | |
hsa-miR-101-3p | glioblastoma | progression | "miR 101 is down regulated in glioblastoma resultin ......" | 21321380 | |
hsa-miR-101-3p | glioblastoma | poor survival | "miR 101 acts as a tumor suppressor by targeting Kr ......" | 25230316 | Luciferase |
hsa-miR-101-3p | head and neck cancer | malignant trasformation | "A global miRNA profiling was performed on 12 sampl ......" | 21637912 | |
hsa-miR-101-3p | kidney renal cell cancer | cell migration | "Restoration of miR-101 significantly inhibited cel ......" | 27487138 | |
hsa-miR-101-3p | liver cancer | tumorigenesis | "miR-101 a significantly down-regulated miRNA was f ......" | 19155302 | Luciferase |
hsa-miR-101-3p | liver cancer | worse prognosis; progression | "Ectopic expression of miR-101 significantly inhibi ......" | 23178713 | |
hsa-miR-101-3p | liver cancer | drug resistance | "miR 101 inhibits autophagy and enhances cisplatin ......" | 23483142 | |
hsa-miR-101-3p | liver cancer | tumorigenesis; malignant trasformation; worse prognosis | "Furthermore miR-101 an important tumor-suppressive ......" | 24002871 | |
hsa-miR-101-3p | liver cancer | progression | "Oncogene polycomb group protein enhancer of zeste ......" | 24211739 | Luciferase; Colony formation |
hsa-miR-101-3p | liver cancer | worse prognosis; tumor size; progression | "Based on our prior observations that miRNA-101 miR ......" | 24260081 | |
hsa-miR-101-3p | liver cancer | metastasis; poor survival; tumorigenesis | "However the efficacy of miR-101 replacement therap ......" | 25693145 | |
hsa-miR-101-3p | liver cancer | progression | "Single Nucleotide Polymorphisms in miR 149 rs22928 ......" | 26434859 | |
hsa-miR-101-3p | liver cancer | tumorigenesis | "Reciprocal negative feedback loop between EZH2 and ......" | 26718325 | |
hsa-miR-101-3p | liver cancer | metastasis; cell migration | "miRNA miR-101 has been suggested to be associated ......" | 26870229 | |
hsa-miR-101-3p | lung cancer | tumorigenesis | "miR 101 DNA copy loss is a prominent subtype speci ......" | 21849855 | |
hsa-miR-101-3p | lung cancer | tumorigenesis; metastasis | "Restoration of miR 101 suppresses lung tumorigenes ......" | 25210796 | Luciferase |
hsa-miR-101-3p | lung cancer | progression | "At the same time microRNA-101 mir-101 was found to ......" | 25428391 | |
hsa-miR-101-3p | lung cancer | metastasis | "miR 101 represses lung cancer by inhibiting intera ......" | 26349988 | |
hsa-miR-101-3p | lung cancer | progression | "The deregulation of miR-101 has been implicated in ......" | 26628987 | Luciferase |
hsa-miR-101-3p | lung squamous cell cancer | drug resistance | "In this study we investigate whether miRNA miR-101 ......" | 21270667 | Luciferase |
hsa-miR-101-3p | lung squamous cell cancer | staging; worse prognosis; poor survival; progression | "MiR 101 and Mcl 1 in non small cell lung cancer: e ......" | 21993632 | Western blot |
hsa-miR-101-3p | lung squamous cell cancer | drug resistance; malignant trasformation | "Radiosensitizing effects of ectopic miR 101 on non ......" | 22014955 | Western blot |
hsa-miR-101-3p | lymphoma | differentiation | "MicroRNA profiles were correlated with correspondi ......" | 21960592 | |
hsa-miR-101-3p | melanoma | staging; poor survival | "MiR 101 inhibits melanoma cell invasion and prolif ......" | 23962556 | |
hsa-miR-101-3p | ovarian cancer | motility | "MicroRNA-101 miR-101 expression is negatively asso ......" | 21818714 | Wound Healing Assay |
hsa-miR-101-3p | ovarian cancer | cell migration | "MiR 101 suppresses the epithelial to mesenchymal t ......" | 24677166 | |
hsa-miR-101-3p | ovarian cancer | progression; drug resistance; malignant trasformation; tumorigenesis; staging; differentiation | "miR 101 regulates expression of EZH2 and contribut ......" | 25260883 | |
hsa-miR-101-3p | pancreatic cancer | tumorigenesis | "miR-122 let-7 family and miR-101 are down-regulate ......" | 22303361 | |
hsa-miR-101-3p | pancreatic cancer | staging; metastasis; poor survival | "miR-101 is an outstanding tumor suppressor in vari ......" | 25968875 | Western blot; Luciferase |
hsa-miR-101-3p | prostate cancer | malignant trasformation | "The expression of nine selected miRNAs hsa-miR-101 ......" | 24517338 | Luciferase |
hsa-miR-101-3p | prostate cancer | progression; tumorigenesis | "RLIP76 dependent suppression of PI3K/AKT/Bcl 2 pat ......" | 26067553 | Flow cytometry; MTT assay |
hsa-miR-101-3p | prostate cancer | metastasis; progression | "Some of the genes that are negatively regulated by ......" | 27270442 | |
hsa-miR-101-3p | retinoblastoma | progression | "MiR 101 downregulated in retinoblastoma functions ......" | 24807198 | |
hsa-miR-101-3p | sarcoma | cell migration | "miR-101 is downregulated in various types of cance ......" | 25190211 | |
hsa-miR-101-3p | thyroid cancer | metastasis; cell migration | "In previous studies the role of miRNA-101 miR-101 ......" | 25202416 | Luciferase |
Reported gene related to hsa-miR-101-3p
miRNA | cancer | gene | reporting | PUBMED |
---|---|---|---|---|
hsa-miR-101-3p | bladder cancer | EZH2 | "Methyl jasmonate sensitizes human bladder cancer c ......" | 24490857 |
hsa-miR-101-3p | breast cancer | EZH2 | "Main objective of the present study is to investig ......" | 22094936 |
hsa-miR-101-3p | esophageal cancer | EZH2 | "miR 101 suppresses tumor proliferation and migrati ......" | 25400732 |
hsa-miR-101-3p | gastric cancer | EZH2 | "Long non coding RNA XIST regulates gastric cancer ......" | 27620004 |
hsa-miR-101-3p | gastric cancer | EZH2 | "Moreover around 40% of cases showing miR-101 down- ......" | 22450781 |
hsa-miR-101-3p | glioblastoma | EZH2 | "miR 101 is down regulated in glioblastoma resultin ......" | 21321380 |
hsa-miR-101-3p | liver cancer | EZH2 | "miR-101 in turn inhibits the expression of two sub ......" | 24002871 |
hsa-miR-101-3p | liver cancer | EZH2 | "Reporter gene assays revealed that ectopic express ......" | 26718325 |
hsa-miR-101-3p | liver cancer | EZH2 | "The aim of our study was to investigate the functi ......" | 24211739 |
hsa-miR-101-3p | lung cancer | EZH2 | "The results showed that mir-101 was down-regulated ......" | 25428391 |
hsa-miR-101-3p | lung cancer | EZH2 | "Therefore we aimed to ascertain whether or not the ......" | 22977606 |
hsa-miR-101-3p | lung squamous cell cancer | EZH2 | "In this study we investigate whether miRNA miR-101 ......" | 21270667 |
hsa-miR-101-3p | melanoma | EZH2 | "MiR 101 inhibits melanoma cell invasion and prolif ......" | 23962556 |
hsa-miR-101-3p | ovarian cancer | EZH2 | "We explore the role of miR-101 and its interaction ......" | 21818714 |
hsa-miR-101-3p | ovarian cancer | EZH2 | "miR 101 regulates expression of EZH2 and contribut ......" | 25260883 |
hsa-miR-101-3p | pancreatic cancer | EZH2 | "Mechanistic investigations revealed that reexpress ......" | 22108826 |
hsa-miR-101-3p | retinoblastoma | EZH2 | "MiR 101 downregulated in retinoblastoma functions ......" | 24807198 |
hsa-miR-101-3p | sarcoma | EZH2 | "MiR-101 is a microRNA involved in a negative feedb ......" | 26251675 |
hsa-miR-101-3p | sarcoma | EZH2 | "In the present study we reported that ectopic over ......" | 25190211 |
hsa-miR-101-3p | bladder cancer | PTGS2 | "Enforced expression of miR 101 enhances cisplatin ......" | 25109742 |
hsa-miR-101-3p | cervical and endocervical cancer | PTGS2 | "The expression of COX-2 in Hela cell was also exam ......" | 24289600 |
hsa-miR-101-3p | cervical and endocervical cancer | PTGS2 | "Immunohistochemistry was performed to assess prote ......" | 26617722 |
hsa-miR-101-3p | cervical and endocervical cancer | PTGS2 | "Roles of MiR 101 and its target gene Cox 2 in earl ......" | 24528073 |
hsa-miR-101-3p | colon cancer | PTGS2 | "MiR 101 downregulation is involved in cyclooxygena ......" | 19133256 |
hsa-miR-101-3p | esophageal cancer | PTGS2 | "Luciferase assay revealed that COX-2 was a direct ......" | 26530100 |
hsa-miR-101-3p | esophageal cancer | PTGS2 | "Cyclooxygenase 2 a Potential Therapeutic Target Is ......" | 26556718 |
hsa-miR-101-3p | gastric cancer | PTGS2 | "Expressions of COX 2 PKC α and miR 101 in gastric ......" | 23644120 |
hsa-miR-101-3p | gastric cancer | PTGS2 | "Downregulation of miR 101 in gastric cancer correl ......" | 23013439 |
hsa-miR-101-3p | liver cancer | PTGS2 | "MiR-16 and miR-101 levels do not correlate with CO ......" | 24759835 |
hsa-miR-101-3p | lung cancer | PTGS2 | "Interestingly cyclooxygenase-2 inhibition by aspir ......" | 24958470 |
hsa-miR-101-3p | prostate cancer | PTGS2 | "Enforced expression of miR 101 inhibits prostate c ......" | 21430074 |
hsa-miR-101-3p | breast cancer | CDH1 | "The overexpression of miR-101 resulted in downregu ......" | 26927545 |
hsa-miR-101-3p | gastric cancer | CDH1 | "Moreover around 40% of cases showing miR-101 down- ......" | 22450781 |
hsa-miR-101-3p | lung cancer | CDH1 | "A reduction in the trimethyl H3K27 histone mark wa ......" | 22977606 |
hsa-miR-101-3p | ovarian cancer | CDH1 | "Our findings showed that miR-101 represents a redu ......" | 24677166 |
hsa-miR-101-3p | breast cancer | MCL1 | "The aim of our study was to investigate the functi ......" | 26036638 |
hsa-miR-101-3p | liver cancer | MCL1 | "Moreover silencing of Mcl-1 phenocopied the effect ......" | 19155302 |
hsa-miR-101-3p | lung squamous cell cancer | MCL1 | "MiR 101 and Mcl 1 in non small cell lung cancer: e ......" | 21993632 |
hsa-miR-101-3p | colorectal cancer | RAC1 | "Mir-101 inhibitors significantly increased the luc ......" | 25057058 |
hsa-miR-101-3p | thyroid cancer | RAC1 | "In previous studies the role of miRNA-101 miR-101 ......" | 25202416 |
hsa-miR-101-3p | thyroid cancer | RAC1 | "miR 101 inhibits cell proliferation by targeting R ......" | 24649082 |
hsa-miR-101-3p | liver cancer | CXCL12 | "Vascular mimicry formation is promoted by paracrin ......" | 27693460 |
hsa-miR-101-3p | lung cancer | CXCL12 | "miR 101 represses lung cancer by inhibiting intera ......" | 26349988 |
hsa-miR-101-3p | breast cancer | DNMT3A | "The expressions of miR-101 and DNA methyltransfera ......" | 26927545 |
hsa-miR-101-3p | lung cancer | DNMT3A | "Restoration of miR 101 suppresses lung tumorigenes ......" | 25210796 |
hsa-miR-101-3p | lymphoma | MTOR | "Furthermore inhibition of mTOR which is targeted b ......" | 20805506 |
hsa-miR-101-3p | sarcoma | MTOR | "Meanwhile bioinformatic analysis demonstrated that ......" | 25480586 |
hsa-miR-101-3p | liver cancer | MYC | "In addition co-overexpression of c-Myc and EZH2 in ......" | 24002871 |
hsa-miR-101-3p | liver cancer | MYC | "Furthermore miR-101 significantly suppressed both ......" | 25762642 |
hsa-miR-101-3p | gastric cancer | SOCS2 | "MiR 101 inhibits cell growth and tumorigenesis of ......" | 25561270 |
hsa-miR-101-3p | ovarian cancer | SOCS2 | "Real time polymerase chain reaction RT-PCR was emp ......" | 26884939 |
hsa-miR-101-3p | bladder cancer | VEGFC | "miR-101 and VEGF-C interference independently enha ......" | 25658842 |
hsa-miR-101-3p | liver cancer | VEGFC | "Vascular endothelial growth factor VEGF-C was furt ......" | 26870229 |
hsa-miR-101-3p | breast cancer | ACKR3 | "CX chemokine receptor 7 CXCR7 is a direct target o ......" | 26360780 |
hsa-miR-101-3p | prostate cancer | AR | "Since miR-101 is an inhibitor of autophagy and its ......" | 26473737 |
hsa-miR-101-3p | lung squamous cell cancer | ATM | "Although ectopic miR-101 efficiently decreased the ......" | 22014955 |
hsa-miR-101-3p | head and neck cancer | BRIP1 | "Further functional analyses showed that SNP rs7213 ......" | 26711789 |
hsa-miR-101-3p | lung cancer | CDKN2A | "Finally miR-101 deletions on 9p were exclusive of ......" | 21849855 |
hsa-miR-101-3p | esophageal cancer | CSE | "Taken together our findings revealed a new post-tr ......" | 26530100 |
hsa-miR-101-3p | liver cancer | EED | "miR-101 in turn inhibits the expression of two sub ......" | 24002871 |
hsa-miR-101-3p | pancreatic cancer | EPCAM | "Mechanistic investigations revealed that reexpress ......" | 22108826 |
hsa-miR-101-3p | cervical and endocervical cancer | FOS | "miR 101 inhibits the G1 to S phase transition of c ......" | 24987920 |
hsa-miR-101-3p | pancreatic cancer | HMGA2 | "We identified high-mobility group AT-hook 2 HMGA2 ......" | 25968875 |
hsa-miR-101-3p | liver cancer | IKBKG | "MiR 101 functions as a tumor suppressor by directl ......" | 24189458 |
hsa-miR-101-3p | breast cancer | JAK2 | "miR 101 promotes breast cancer cell apoptosis by t ......" | 25059472 |
hsa-miR-101-3p | glioblastoma | KLF6 | "One direct target of miR-101 the transcription fac ......" | 25230316 |
hsa-miR-101-3p | thyroid cancer | KRT1 | "Restoration of miR-101 expression significantly in ......" | 24649082 |
hsa-miR-101-3p | lung cancer | LIN28B | "Lin28B was identified as critical effector target ......" | 24958470 |
hsa-miR-101-3p | esophageal cancer | MALAT1 | "Silencing of long noncoding RNA MALAT1 by miR 101 ......" | 25538231 |
hsa-miR-101-3p | lung cancer | MARK1 | "A reduction in the trimethyl H3K27 histone mark wa ......" | 22977606 |
hsa-miR-101-3p | bladder cancer | MET | "We found that miR-101 directly targets c-Met via i ......" | 23618864 |
hsa-miR-101-3p | pancreatic cancer | MIA | "MIA PaCa-2 and PANC-1 cells transfected with miR-1 ......" | 25841339 |
hsa-miR-101-3p | melanoma | MITF | "MiR 101 inhibits melanoma cell invasion and prolif ......" | 23962556 |
hsa-miR-101-3p | lung cancer | MMP2 | "Moreover the expression of CDH1 and MMP-2 was reve ......" | 22977606 |
hsa-miR-101-3p | liver cancer | NLK | "MiR 101 functions as a tumor suppressor by directl ......" | 24189458 |
hsa-miR-101-3p | pancreatic cancer | PKM | "miR-101 or miR-24-2 over-expressing cells when tre ......" | 25841339 |
hsa-miR-101-3p | lung squamous cell cancer | PRKDC | "Although ectopic miR-101 efficiently decreased the ......" | 22014955 |
hsa-miR-101-3p | colon cancer | PTGER4 | "MicroRNA 101 miR 101 post transcriptionally regula ......" | 22353936 |
hsa-miR-101-3p | liver cancer | RAB5A | "Downregulation of miR 101 3p by hepatitis B virus ......" | 24788845 |
hsa-miR-101-3p | prostate cancer | RALA | "To verify the mechanisms we identified a novel miR ......" | 26067553 |
hsa-miR-101-3p | prostate cancer | RALBP1 | "RLIP76 dependent suppression of PI3K/AKT/Bcl 2 pat ......" | 26067553 |
hsa-miR-101-3p | liver cancer | RAP1B | "Functional analysis of miR 101 3p and Rap1b involv ......" | 24697700 |
hsa-miR-101-3p | lung cancer | RUNX1 | "Mechanistically we indicated that miR-101 inversel ......" | 26628987 |
hsa-miR-101-3p | liver cancer | SNHG6 | "SNHG6 may act as a competing endogenous RNA effect ......" | 27702662 |
hsa-miR-101-3p | colorectal cancer | SNORD44 | "MiR-101 was hardly expressed in the tumor samples ......" | 23121918 |
hsa-miR-101-3p | liver cancer | SOX9 | "Ectopic expression of miR-101 significantly inhibi ......" | 23178713 |
hsa-miR-101-3p | colorectal cancer | SPHK1 | "In the current study we demonstrate that microRNA- ......" | 26071354 |
hsa-miR-101-3p | breast cancer | STAT3 | "STAT3 signaling downstream of CXCR7 is involved in ......" | 26360780 |
hsa-miR-101-3p | prostate cancer | SUB1 | "Thus our study suggests that miR-101 loss results ......" | 27270442 |
hsa-miR-101-3p | prostate cancer | TNMD | "We first demonstrated that miR-101 treatment promo ......" | 26067553 |
hsa-miR-101-3p | liver cancer | TRIB3 | "SNHG6 may act as a competing endogenous RNA effect ......" | 27702662 |
hsa-miR-101-3p | gastric cancer | XIST | "Long non coding RNA XIST regulates gastric cancer ......" | 27620004 |
hsa-miR-101-3p | ovarian cancer | ZEB1 | "MiR 101 suppresses the epithelial to mesenchymal t ......" | 24677166 |
hsa-miR-101-3p | ovarian cancer | ZEB2 | "MiR 101 suppresses the epithelial to mesenchymal t ......" | 24677166 |
Expression profile in cancer corhorts:
Putative target regulations
miRNA | Gene | Cancer | Interaction | Correlation beta |
---|---|---|---|---|
hsa-miR-101-3p | ATP5B | 9 cancers: BLCA; BRCA; COAD; KIRC; LUAD; LUSC; PRAD; THCA; STAD | miRNAWalker2 validate; miRTarBase | TCGA BLCA -0.082; TCGA BRCA -0.133; TCGA COAD -0.144; TCGA KIRC -0.252; TCGA LUAD -0.081; TCGA LUSC -0.169; TCGA PRAD -0.074; TCGA THCA -0.155; TCGA STAD -0.165 |
hsa-miR-101-3p | BIRC5 | 15 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; PRAD; SARC; UCEC | miRNAWalker2 validate | TCGA BLCA -0.216; TCGA BRCA -0.558; TCGA CESC -0.197; TCGA ESCA -0.517; TCGA HNSC -0.431; TCGA KIRP -0.601; TCGA LGG -0.564; TCGA LIHC -1.327; TCGA LUAD -0.312; TCGA LUSC -1.143; TCGA OV -0.31; TCGA PAAD -0.581; TCGA PRAD -0.383; TCGA SARC -0.284; TCGA UCEC -0.595 |
hsa-miR-101-3p | FBN2 | 11 cancers: BLCA; BRCA; CESC; HNSC; KIRC; LGG; LIHC; LUSC; OV; SARC; THCA | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BLCA -0.352; TCGA BRCA -0.449; TCGA CESC -0.596; TCGA HNSC -0.584; TCGA KIRC -0.83; TCGA LGG -0.224; TCGA LIHC -0.276; TCGA LUSC -0.735; TCGA OV -0.552; TCGA SARC -0.359; TCGA THCA -0.279 |
hsa-miR-101-3p | FZD6 | 10 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; LIHC; LUSC; PAAD; SARC; STAD | miRNAWalker2 validate; MirTarget | TCGA BLCA -0.15; TCGA BRCA -0.184; TCGA ESCA -0.537; TCGA HNSC -0.152; TCGA KIRC -0.493; TCGA LIHC -0.313; TCGA LUSC -0.266; TCGA PAAD -0.327; TCGA SARC -0.677; TCGA STAD -0.187 |
hsa-miR-101-3p | GNB1 | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LIHC; OV; THCA; STAD; UCEC | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BLCA -0.136; TCGA BRCA -0.075; TCGA CESC -0.088; TCGA ESCA -0.113; TCGA HNSC -0.15; TCGA LIHC -0.066; TCGA OV -0.066; TCGA THCA -0.107; TCGA STAD -0.113; TCGA UCEC -0.088 |
hsa-miR-101-3p | KIF2C | 16 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; PRAD; SARC; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.282; TCGA BRCA -0.453; TCGA CESC -0.136; TCGA ESCA -0.36; TCGA HNSC -0.276; TCGA KIRP -0.297; TCGA LGG -0.323; TCGA LIHC -1.297; TCGA LUAD -0.291; TCGA LUSC -1.022; TCGA OV -0.186; TCGA PAAD -0.384; TCGA PRAD -0.262; TCGA SARC -0.292; TCGA STAD -0.342; TCGA UCEC -0.416 |
hsa-miR-101-3p | LBR | 11 cancers: BLCA; BRCA; ESCA; KIRC; KIRP; LGG; LIHC; LUSC; OV; SARC; STAD | miRNAWalker2 validate | TCGA BLCA -0.197; TCGA BRCA -0.163; TCGA ESCA -0.183; TCGA KIRC -0.135; TCGA KIRP -0.154; TCGA LGG -0.14; TCGA LIHC -0.156; TCGA LUSC -0.141; TCGA OV -0.212; TCGA SARC -0.186; TCGA STAD -0.252 |
hsa-miR-101-3p | LMNB1 | 10 cancers: BLCA; BRCA; LGG; LIHC; LUAD; LUSC; OV; SARC; THCA; UCEC | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BLCA -0.144; TCGA BRCA -0.28; TCGA LGG -0.321; TCGA LIHC -0.363; TCGA LUAD -0.139; TCGA LUSC -0.443; TCGA OV -0.156; TCGA SARC -0.295; TCGA THCA -0.128; TCGA UCEC -0.337 |
hsa-miR-101-3p | MAP2K1 | 9 cancers: BLCA; BRCA; CESC; COAD; ESCA; LUSC; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.179; TCGA BRCA -0.158; TCGA CESC -0.21; TCGA COAD -0.185; TCGA ESCA -0.211; TCGA LUSC -0.078; TCGA SARC -0.143; TCGA THCA -0.133; TCGA STAD -0.118 |
hsa-miR-101-3p | PPP4R1 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; OV; PAAD; SARC; THCA; STAD | miRNAWalker2 validate | TCGA BLCA -0.156; TCGA BRCA -0.073; TCGA CESC -0.13; TCGA COAD -0.165; TCGA ESCA -0.288; TCGA HNSC -0.18; TCGA LGG -0.075; TCGA LIHC -0.165; TCGA OV -0.096; TCGA PAAD -0.284; TCGA SARC -0.081; TCGA THCA -0.083; TCGA STAD -0.124 |
hsa-miR-101-3p | PTGS2 | 9 cancers: BLCA; COAD; ESCA; HNSC; KIRC; LUAD; PAAD; SARC; STAD | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BLCA -0.546; TCGA COAD -0.466; TCGA ESCA -0.694; TCGA HNSC -0.296; TCGA KIRC -0.957; TCGA LUAD -0.25; TCGA PAAD -0.656; TCGA SARC -0.568; TCGA STAD -0.495 |
hsa-miR-101-3p | RTN4 | 9 cancers: BLCA; BRCA; COAD; ESCA; HNSC; KIRC; LUAD; PAAD; PRAD | miRNAWalker2 validate | TCGA BLCA -0.166; TCGA BRCA -0.094; TCGA COAD -0.12; TCGA ESCA -0.367; TCGA HNSC -0.186; TCGA KIRC -0.245; TCGA LUAD -0.076; TCGA PAAD -0.216; TCGA PRAD -0.097 |
hsa-miR-101-3p | STAMBP | 9 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; LIHC; LUSC; PAAD | miRNAWalker2 validate; MirTarget | TCGA BLCA -0.089; TCGA BRCA -0.158; TCGA CESC -0.081; TCGA ESCA -0.1; TCGA HNSC -0.102; TCGA KIRC -0.132; TCGA LIHC -0.071; TCGA LUSC -0.235; TCGA PAAD -0.126 |
hsa-miR-101-3p | TGFBR1 | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LGG; OV; STAD | miRNAWalker2 validate; miRNATAP | TCGA BLCA -0.356; TCGA BRCA -0.226; TCGA CESC -0.258; TCGA COAD -0.173; TCGA ESCA -0.334; TCGA HNSC -0.137; TCGA KIRC -0.167; TCGA LGG -0.069; TCGA OV -0.077; TCGA STAD -0.159 |
hsa-miR-101-3p | TMTC3 | 12 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LUAD; LUSC; OV; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BLCA -0.151; TCGA BRCA -0.194; TCGA COAD -0.225; TCGA ESCA -0.553; TCGA HNSC -0.08; TCGA LUAD -0.084; TCGA LUSC -0.33; TCGA OV -0.153; TCGA SARC -0.135; TCGA THCA -0.103; TCGA STAD -0.144; TCGA UCEC -0.066 |
hsa-miR-101-3p | VAPA | 9 cancers: BLCA; CESC; COAD; ESCA; HNSC; KIRC; PAAD; PRAD; STAD | miRNAWalker2 validate | TCGA BLCA -0.147; TCGA CESC -0.068; TCGA COAD -0.191; TCGA ESCA -0.136; TCGA HNSC -0.067; TCGA KIRC -0.072; TCGA PAAD -0.118; TCGA PRAD -0.07; TCGA STAD -0.108 |
hsa-miR-101-3p | VEZT | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; OV; SARC | miRNAWalker2 validate | TCGA BLCA -0.138; TCGA BRCA -0.12; TCGA CESC -0.075; TCGA COAD -0.22; TCGA ESCA -0.334; TCGA HNSC -0.082; TCGA KIRC -0.076; TCGA KIRP -0.089; TCGA OV -0.07; TCGA SARC -0.162 |
hsa-miR-101-3p | CDKN1A | 11 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LUAD; OV; PAAD; PRAD; THCA; UCEC | MirTarget | TCGA BLCA -0.196; TCGA BRCA -0.125; TCGA COAD -0.404; TCGA ESCA -0.448; TCGA HNSC -0.259; TCGA LUAD -0.077; TCGA OV -0.185; TCGA PAAD -0.313; TCGA PRAD -0.32; TCGA THCA -0.481; TCGA UCEC -0.322 |
hsa-miR-101-3p | UBE2F | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LUAD; LUSC; OV; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.221; TCGA BRCA -0.17; TCGA CESC -0.115; TCGA COAD -0.094; TCGA ESCA -0.135; TCGA HNSC -0.226; TCGA KIRC -0.19; TCGA LUAD -0.065; TCGA LUSC -0.147; TCGA OV -0.1; TCGA PRAD -0.125; TCGA STAD -0.11; TCGA UCEC -0.131 |
hsa-miR-101-3p | DIP2B | 9 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LUAD; LUSC; THCA; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.247; TCGA BRCA -0.131; TCGA CESC -0.131; TCGA ESCA -0.396; TCGA HNSC -0.1; TCGA LUAD -0.081; TCGA LUSC -0.281; TCGA THCA -0.147; TCGA UCEC -0.07 |
hsa-miR-101-3p | ZFAND3 | 11 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; LGG; LIHC; OV; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.095; TCGA BRCA -0.067; TCGA CESC -0.126; TCGA COAD -0.075; TCGA HNSC -0.05; TCGA KIRC -0.095; TCGA LGG -0.073; TCGA LIHC -0.054; TCGA OV -0.058; TCGA THCA -0.1; TCGA STAD -0.15 |
hsa-miR-101-3p | TLK2 | 10 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; STAD | MirTarget | TCGA BLCA -0.054; TCGA BRCA -0.136; TCGA ESCA -0.198; TCGA HNSC -0.063; TCGA KIRC -0.061; TCGA KIRP -0.081; TCGA LIHC -0.093; TCGA LUAD -0.057; TCGA LUSC -0.072; TCGA STAD -0.122 |
hsa-miR-101-3p | KPNB1 | 11 cancers: BLCA; BRCA; CESC; ESCA; LIHC; LUAD; LUSC; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.162; TCGA BRCA -0.094; TCGA CESC -0.13; TCGA ESCA -0.161; TCGA LIHC -0.14; TCGA LUAD -0.079; TCGA LUSC -0.159; TCGA SARC -0.17; TCGA THCA -0.109; TCGA STAD -0.157; TCGA UCEC -0.075 |
hsa-miR-101-3p | POMP | 11 cancers: BLCA; BRCA; CESC; HNSC; LUAD; LUSC; OV; PAAD; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.177; TCGA BRCA -0.219; TCGA CESC -0.089; TCGA HNSC -0.158; TCGA LUAD -0.067; TCGA LUSC -0.094; TCGA OV -0.183; TCGA PAAD -0.173; TCGA PRAD -0.157; TCGA STAD -0.144; TCGA UCEC -0.137 |
hsa-miR-101-3p | TIMM17A | 14 cancers: BLCA; BRCA; CESC; COAD; HNSC; KIRC; LUSC; OV; PAAD; PRAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.184; TCGA BRCA -0.226; TCGA CESC -0.062; TCGA COAD -0.147; TCGA HNSC -0.161; TCGA KIRC -0.083; TCGA LUSC -0.187; TCGA OV -0.079; TCGA PAAD -0.183; TCGA PRAD -0.169; TCGA SARC -0.129; TCGA THCA -0.078; TCGA STAD -0.261; TCGA UCEC -0.1 |
hsa-miR-101-3p | XPO5 | 12 cancers: BLCA; BRCA; CESC; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; THCA; STAD | MirTarget | TCGA BLCA -0.157; TCGA BRCA -0.202; TCGA CESC -0.174; TCGA HNSC -0.14; TCGA KIRC -0.168; TCGA KIRP -0.139; TCGA LGG -0.102; TCGA LIHC -0.277; TCGA LUAD -0.073; TCGA LUSC -0.364; TCGA THCA -0.092; TCGA STAD -0.348 |
hsa-miR-101-3p | DENR | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; PRAD; STAD | MirTarget | TCGA BLCA -0.104; TCGA BRCA -0.145; TCGA CESC -0.093; TCGA COAD -0.092; TCGA ESCA -0.242; TCGA HNSC -0.105; TCGA KIRC -0.159; TCGA KIRP -0.148; TCGA LIHC -0.205; TCGA LUAD -0.074; TCGA LUSC -0.253; TCGA PRAD -0.056; TCGA STAD -0.237 |
hsa-miR-101-3p | DNM1L | 11 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; STAD | MirTarget | TCGA BLCA -0.086; TCGA BRCA -0.144; TCGA CESC -0.079; TCGA COAD -0.124; TCGA ESCA -0.23; TCGA HNSC -0.084; TCGA KIRC -0.249; TCGA LIHC -0.2; TCGA LUAD -0.085; TCGA LUSC -0.196; TCGA STAD -0.189 |
hsa-miR-101-3p | PRR11 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; LIHC; LUAD; LUSC; OV; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.617; TCGA BRCA -0.658; TCGA CESC -0.493; TCGA COAD -0.232; TCGA ESCA -0.591; TCGA LIHC -0.678; TCGA LUAD -0.259; TCGA LUSC -0.627; TCGA OV -0.197; TCGA SARC -0.665; TCGA THCA -0.353; TCGA UCEC -0.351 |
hsa-miR-101-3p | MTMR2 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; LUSC; OV; PAAD; SARC; THCA | MirTarget; miRNATAP | TCGA BLCA -0.211; TCGA BRCA -0.199; TCGA CESC -0.15; TCGA COAD -0.119; TCGA ESCA -0.155; TCGA HNSC -0.124; TCGA LIHC -0.396; TCGA LUAD -0.098; TCGA LUSC -0.121; TCGA OV -0.085; TCGA PAAD -0.144; TCGA SARC -0.21; TCGA THCA -0.094 |
hsa-miR-101-3p | UGGT1 | 12 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LIHC; LUAD; LUSC; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.179; TCGA BRCA -0.185; TCGA CESC -0.149; TCGA ESCA -0.158; TCGA KIRC -0.199; TCGA LIHC -0.122; TCGA LUAD -0.079; TCGA LUSC -0.132; TCGA SARC -0.121; TCGA THCA -0.217; TCGA STAD -0.112; TCGA UCEC -0.179 |
hsa-miR-101-3p | KIF5B | 10 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LIHC; LUAD; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.173; TCGA BRCA -0.152; TCGA CESC -0.103; TCGA ESCA -0.222; TCGA KIRC -0.15; TCGA LIHC -0.134; TCGA LUAD -0.051; TCGA SARC -0.133; TCGA THCA -0.099; TCGA STAD -0.191 |
hsa-miR-101-3p | ENY2 | 10 cancers: BLCA; BRCA; COAD; ESCA; HNSC; LIHC; LUSC; PAAD; STAD; UCEC | MirTarget | TCGA BLCA -0.111; TCGA BRCA -0.183; TCGA COAD -0.16; TCGA ESCA -0.213; TCGA HNSC -0.224; TCGA LIHC -0.138; TCGA LUSC -0.212; TCGA PAAD -0.126; TCGA STAD -0.153; TCGA UCEC -0.117 |
hsa-miR-101-3p | NOTCH1 | 9 cancers: BLCA; ESCA; LGG; LIHC; OV; PAAD; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.145; TCGA ESCA -0.41; TCGA LGG -0.187; TCGA LIHC -0.126; TCGA OV -0.147; TCGA PAAD -0.169; TCGA THCA -0.188; TCGA STAD -0.201; TCGA UCEC -0.116 |
hsa-miR-101-3p | SRPK2 | 9 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; LIHC; LUSC; THCA | MirTarget; miRNATAP | TCGA BLCA -0.075; TCGA BRCA -0.101; TCGA CESC -0.177; TCGA ESCA -0.348; TCGA HNSC -0.168; TCGA KIRC -0.173; TCGA LIHC -0.148; TCGA LUSC -0.167; TCGA THCA -0.124 |
hsa-miR-101-3p | ASAP1 | 9 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LIHC; LUAD; SARC; THCA | MirTarget; miRNATAP | TCGA BLCA -0.308; TCGA BRCA -0.154; TCGA CESC -0.122; TCGA ESCA -0.301; TCGA HNSC -0.092; TCGA LIHC -0.416; TCGA LUAD -0.137; TCGA SARC -0.187; TCGA THCA -0.22 |
hsa-miR-101-3p | HTRA3 | 10 cancers: BLCA; BRCA; ESCA; HNSC; LIHC; LUAD; LUSC; OV; PAAD; THCA | MirTarget; miRNATAP | TCGA BLCA -1.146; TCGA BRCA -0.165; TCGA ESCA -0.457; TCGA HNSC -0.53; TCGA LIHC -0.673; TCGA LUAD -0.186; TCGA LUSC -0.229; TCGA OV -0.315; TCGA PAAD -0.5; TCGA THCA -0.227 |
hsa-miR-101-3p | KIF2A | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRC; LIHC; LUSC; OV; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.239; TCGA BRCA -0.117; TCGA CESC -0.098; TCGA COAD -0.138; TCGA ESCA -0.139; TCGA KIRC -0.351; TCGA LIHC -0.29; TCGA LUSC -0.072; TCGA OV -0.07; TCGA SARC -0.131; TCGA THCA -0.152; TCGA UCEC -0.095 |
hsa-miR-101-3p | ASCC3 | 9 cancers: BLCA; BRCA; CESC; ESCA; LGG; LUSC; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.218; TCGA BRCA -0.206; TCGA CESC -0.146; TCGA ESCA -0.187; TCGA LGG -0.052; TCGA LUSC -0.101; TCGA SARC -0.192; TCGA THCA -0.275; TCGA UCEC -0.09 |
hsa-miR-101-3p | UBE2A | 12 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; LIHC; LUSC; OV; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.185; TCGA BRCA -0.212; TCGA ESCA -0.267; TCGA HNSC -0.078; TCGA KIRC -0.155; TCGA LIHC -0.184; TCGA LUSC -0.112; TCGA OV -0.076; TCGA SARC -0.104; TCGA THCA -0.084; TCGA STAD -0.165; TCGA UCEC -0.073 |
hsa-miR-101-3p | NAV1 | 11 cancers: BLCA; BRCA; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; OV; SARC; UCEC | MirTarget | TCGA BLCA -0.428; TCGA BRCA -0.199; TCGA ESCA -0.61; TCGA HNSC -0.3; TCGA LGG -0.081; TCGA LIHC -0.139; TCGA LUAD -0.171; TCGA LUSC -0.296; TCGA OV -0.129; TCGA SARC -0.164; TCGA UCEC -0.206 |
hsa-miR-101-3p | DCUN1D1 | 9 cancers: BLCA; BRCA; COAD; ESCA; KIRC; LUSC; OV; SARC; STAD | MirTarget | TCGA BLCA -0.113; TCGA BRCA -0.195; TCGA COAD -0.109; TCGA ESCA -0.284; TCGA KIRC -0.416; TCGA LUSC -0.228; TCGA OV -0.115; TCGA SARC -0.136; TCGA STAD -0.149 |
hsa-miR-101-3p | CHAC2 | 9 cancers: BLCA; BRCA; CESC; COAD; KIRC; LGG; LUSC; OV; SARC | MirTarget | TCGA BLCA -0.266; TCGA BRCA -0.231; TCGA CESC -0.183; TCGA COAD -0.241; TCGA KIRC -0.406; TCGA LGG -0.12; TCGA LUSC -0.417; TCGA OV -0.213; TCGA SARC -0.156 |
hsa-miR-101-3p | B3GALNT2 | 13 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD; UCEC | MirTarget | TCGA BLCA -0.218; TCGA BRCA -0.172; TCGA CESC -0.104; TCGA ESCA -0.24; TCGA KIRC -0.169; TCGA LIHC -0.245; TCGA LUAD -0.072; TCGA LUSC -0.292; TCGA PAAD -0.192; TCGA SARC -0.219; TCGA THCA -0.112; TCGA STAD -0.246; TCGA UCEC -0.121 |
hsa-miR-101-3p | ARNTL2 | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; OV; PAAD; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.729; TCGA BRCA -0.377; TCGA CESC -0.182; TCGA COAD -0.262; TCGA ESCA -0.526; TCGA HNSC -0.155; TCGA LIHC -0.416; TCGA LUSC -0.792; TCGA OV -0.298; TCGA PAAD -0.416; TCGA SARC -0.614; TCGA THCA -0.605; TCGA UCEC -0.191 |
hsa-miR-101-3p | RAB1A | 13 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUSC; OV; PAAD; PRAD; STAD | MirTarget; miRNATAP | TCGA BLCA -0.103; TCGA BRCA -0.205; TCGA CESC -0.107; TCGA COAD -0.117; TCGA ESCA -0.111; TCGA HNSC -0.109; TCGA KIRC -0.137; TCGA LIHC -0.067; TCGA LUSC -0.129; TCGA OV -0.056; TCGA PAAD -0.116; TCGA PRAD -0.054; TCGA STAD -0.085 |
hsa-miR-101-3p | PANK3 | 10 cancers: BLCA; BRCA; CESC; COAD; KIRC; LUSC; OV; SARC; THCA; UCEC | MirTarget | TCGA BLCA -0.153; TCGA BRCA -0.102; TCGA CESC -0.2; TCGA COAD -0.219; TCGA KIRC -0.239; TCGA LUSC -0.118; TCGA OV -0.17; TCGA SARC -0.177; TCGA THCA -0.189; TCGA UCEC -0.116 |
hsa-miR-101-3p | RBBP7 | 10 cancers: BLCA; BRCA; KIRC; LGG; LIHC; LUSC; OV; SARC; STAD; UCEC | MirTarget; miRNATAP | TCGA BLCA -0.084; TCGA BRCA -0.119; TCGA KIRC -0.145; TCGA LGG -0.066; TCGA LIHC -0.171; TCGA LUSC -0.172; TCGA OV -0.082; TCGA SARC -0.155; TCGA STAD -0.171; TCGA UCEC -0.155 |
hsa-miR-101-3p | CDYL | 11 cancers: BLCA; BRCA; CESC; ESCA; HNSC; KIRC; LGG; LIHC; LUSC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.121; TCGA BRCA -0.136; TCGA CESC -0.111; TCGA ESCA -0.233; TCGA HNSC -0.076; TCGA KIRC -0.088; TCGA LGG -0.084; TCGA LIHC -0.163; TCGA LUSC -0.185; TCGA THCA -0.058; TCGA STAD -0.157 |
hsa-miR-101-3p | TMEM167A | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRC; KIRP; LIHC; OV; THCA | MirTarget | TCGA BLCA -0.093; TCGA BRCA -0.187; TCGA CESC -0.091; TCGA COAD -0.168; TCGA ESCA -0.142; TCGA KIRC -0.097; TCGA KIRP -0.078; TCGA LIHC -0.057; TCGA OV -0.086; TCGA THCA -0.112 |
hsa-miR-101-3p | EXOC5 | 9 cancers: BLCA; BRCA; CESC; COAD; ESCA; OV; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.258; TCGA BRCA -0.184; TCGA CESC -0.155; TCGA COAD -0.085; TCGA ESCA -0.373; TCGA OV -0.069; TCGA SARC -0.156; TCGA THCA -0.085; TCGA STAD -0.152 |
hsa-miR-101-3p | RRM1 | 13 cancers: BLCA; BRCA; COAD; ESCA; KIRC; LGG; LIHC; LUSC; PAAD; PRAD; SARC; THCA; STAD | MirTarget; miRNATAP | TCGA BLCA -0.333; TCGA BRCA -0.134; TCGA COAD -0.105; TCGA ESCA -0.248; TCGA KIRC -0.098; TCGA LGG -0.091; TCGA LIHC -0.14; TCGA LUSC -0.32; TCGA PAAD -0.105; TCGA PRAD -0.067; TCGA SARC -0.211; TCGA THCA -0.082; TCGA STAD -0.201 |
hsa-miR-101-3p | RANBP1 | 15 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; PRAD; STAD; UCEC | MirTarget | TCGA BLCA -0.102; TCGA BRCA -0.134; TCGA ESCA -0.199; TCGA HNSC -0.268; TCGA KIRC -0.067; TCGA KIRP -0.078; TCGA LGG -0.122; TCGA LIHC -0.081; TCGA LUAD -0.103; TCGA LUSC -0.439; TCGA OV -0.17; TCGA PAAD -0.202; TCGA PRAD -0.134; TCGA STAD -0.161; TCGA UCEC -0.115 |
hsa-miR-101-3p | DCBLD2 | 9 cancers: BLCA; BRCA; CESC; HNSC; KIRC; KIRP; PAAD; SARC; THCA | MirTarget; miRNATAP | TCGA BLCA -0.633; TCGA BRCA -0.091; TCGA CESC -0.158; TCGA HNSC -0.244; TCGA KIRC -0.641; TCGA KIRP -0.329; TCGA PAAD -0.626; TCGA SARC -0.291; TCGA THCA -0.237 |
hsa-miR-101-3p | JMJD6 | 11 cancers: BLCA; BRCA; HNSC; KIRP; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; STAD | mirMAP | TCGA BLCA -0.118; TCGA BRCA -0.107; TCGA HNSC -0.123; TCGA KIRP -0.151; TCGA LIHC -0.237; TCGA LUAD -0.105; TCGA LUSC -0.099; TCGA PAAD -0.129; TCGA PRAD -0.085; TCGA SARC -0.13; TCGA STAD -0.163 |
hsa-miR-101-3p | TLL2 | 9 cancers: BLCA; BRCA; KIRC; KIRP; LUAD; LUSC; OV; PAAD; THCA | mirMAP | TCGA BLCA -0.315; TCGA BRCA -0.372; TCGA KIRC -1.087; TCGA KIRP -0.69; TCGA LUAD -0.181; TCGA LUSC -0.772; TCGA OV -0.302; TCGA PAAD -0.323; TCGA THCA -0.679 |
hsa-miR-101-3p | CDK6 | 9 cancers: BLCA; CESC; ESCA; HNSC; KIRC; LGG; LUAD; LUSC; THCA | mirMAP | TCGA BLCA -0.728; TCGA CESC -0.422; TCGA ESCA -0.391; TCGA HNSC -0.33; TCGA KIRC -0.23; TCGA LGG -0.214; TCGA LUAD -0.104; TCGA LUSC -0.3; TCGA THCA -0.249 |
hsa-miR-101-3p | CPA4 | 11 cancers: BLCA; BRCA; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; LUSC; SARC; UCEC | mirMAP | TCGA BLCA -1.311; TCGA BRCA -0.278; TCGA ESCA -1.421; TCGA HNSC -0.662; TCGA KIRC -1.112; TCGA KIRP -0.576; TCGA LIHC -0.448; TCGA LUAD -0.312; TCGA LUSC -1.117; TCGA SARC -0.721; TCGA UCEC -0.559 |
hsa-miR-101-3p | G3BP1 | 9 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRC; LUSC; THCA; STAD | mirMAP | TCGA BLCA -0.182; TCGA BRCA -0.138; TCGA CESC -0.143; TCGA COAD -0.117; TCGA ESCA -0.208; TCGA KIRC -0.111; TCGA LUSC -0.153; TCGA THCA -0.096; TCGA STAD -0.177 |
hsa-miR-101-3p | PGAM1 | 14 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.278; TCGA BRCA -0.205; TCGA CESC -0.219; TCGA COAD -0.338; TCGA ESCA -0.382; TCGA HNSC -0.236; TCGA LUAD -0.083; TCGA LUSC -0.331; TCGA PAAD -0.251; TCGA PRAD -0.157; TCGA SARC -0.096; TCGA THCA -0.197; TCGA STAD -0.205; TCGA UCEC -0.225 |
hsa-miR-101-3p | ATP2A2 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; LIHC; LUAD; LUSC; SARC; THCA; STAD; UCEC | mirMAP | TCGA BLCA -0.252; TCGA BRCA -0.185; TCGA CESC -0.154; TCGA COAD -0.131; TCGA ESCA -0.257; TCGA LIHC -0.099; TCGA LUAD -0.093; TCGA LUSC -0.257; TCGA SARC -0.274; TCGA THCA -0.199; TCGA STAD -0.252; TCGA UCEC -0.086 |
hsa-miR-101-3p | PGAM4 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUSC; PAAD; PRAD; SARC; THCA; UCEC | mirMAP | TCGA BLCA -0.333; TCGA BRCA -0.208; TCGA CESC -0.273; TCGA COAD -0.373; TCGA ESCA -0.354; TCGA HNSC -0.137; TCGA LUSC -0.263; TCGA PAAD -0.187; TCGA PRAD -0.134; TCGA SARC -0.24; TCGA THCA -0.265; TCGA UCEC -0.827 |
hsa-miR-101-3p | PURB | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LIHC; LUSC; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.1; TCGA BRCA -0.113; TCGA CESC -0.084; TCGA ESCA -0.224; TCGA HNSC -0.058; TCGA LIHC -0.065; TCGA LUSC -0.159; TCGA SARC -0.099; TCGA THCA -0.059; TCGA STAD -0.144 |
hsa-miR-101-3p | STC1 | 10 cancers: BLCA; BRCA; CESC; COAD; HNSC; LIHC; LUAD; LUSC; SARC; UCEC | miRNATAP | TCGA BLCA -0.208; TCGA BRCA -0.184; TCGA CESC -0.512; TCGA COAD -0.26; TCGA HNSC -0.172; TCGA LIHC -0.229; TCGA LUAD -0.288; TCGA LUSC -0.228; TCGA SARC -0.245; TCGA UCEC -0.398 |
hsa-miR-101-3p | NACC2 | 9 cancers: BLCA; CESC; COAD; HNSC; LUAD; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.517; TCGA CESC -0.29; TCGA COAD -0.269; TCGA HNSC -0.111; TCGA LUAD -0.12; TCGA PAAD -0.363; TCGA SARC -0.339; TCGA THCA -0.243; TCGA STAD -0.28 |
hsa-miR-101-3p | ZNF367 | 11 cancers: BLCA; BRCA; ESCA; LGG; LUAD; LUSC; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.236; TCGA BRCA -0.232; TCGA ESCA -0.302; TCGA LGG -0.165; TCGA LUAD -0.148; TCGA LUSC -0.369; TCGA PRAD -0.193; TCGA SARC -0.221; TCGA THCA -0.169; TCGA STAD -0.273; TCGA UCEC -0.148 |
hsa-miR-101-3p | STRN3 | 9 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LUSC; THCA; STAD | miRNATAP | TCGA BLCA -0.206; TCGA BRCA -0.128; TCGA CESC -0.12; TCGA COAD -0.178; TCGA ESCA -0.385; TCGA HNSC -0.119; TCGA LUSC -0.121; TCGA THCA -0.053; TCGA STAD -0.154 |
hsa-miR-101-3p | EIF4G2 | 10 cancers: BLCA; BRCA; CESC; COAD; ESCA; KIRC; OV; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.122; TCGA BRCA -0.166; TCGA CESC -0.118; TCGA COAD -0.118; TCGA ESCA -0.174; TCGA KIRC -0.085; TCGA OV -0.069; TCGA SARC -0.164; TCGA THCA -0.105; TCGA STAD -0.103 |
hsa-miR-101-3p | FAM199X | 10 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LIHC; LUSC; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.128; TCGA BRCA -0.151; TCGA CESC -0.091; TCGA ESCA -0.161; TCGA KIRC -0.331; TCGA LIHC -0.091; TCGA LUSC -0.185; TCGA THCA -0.191; TCGA STAD -0.176; TCGA UCEC -0.121 |
hsa-miR-101-3p | NID2 | 10 cancers: BLCA; BRCA; CESC; ESCA; HNSC; LGG; LUAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.644; TCGA BRCA -0.357; TCGA CESC -0.213; TCGA ESCA -0.604; TCGA HNSC -0.387; TCGA LGG -0.14; TCGA LUAD -0.197; TCGA SARC -0.401; TCGA THCA -0.143; TCGA STAD -0.438 |
hsa-miR-101-3p | PHLDA1 | 10 cancers: BLCA; CESC; COAD; ESCA; HNSC; LGG; LUSC; OV; PAAD; UCEC | miRNATAP | TCGA BLCA -0.348; TCGA CESC -0.318; TCGA COAD -0.46; TCGA ESCA -0.334; TCGA HNSC -0.151; TCGA LGG -0.216; TCGA LUSC -0.283; TCGA OV -0.195; TCGA PAAD -0.372; TCGA UCEC -0.263 |
hsa-miR-101-3p | MAP7D1 | 9 cancers: BLCA; CESC; COAD; ESCA; HNSC; LIHC; LUAD; PAAD; THCA | miRNATAP | TCGA BLCA -0.383; TCGA CESC -0.125; TCGA COAD -0.112; TCGA ESCA -0.298; TCGA HNSC -0.277; TCGA LIHC -0.262; TCGA LUAD -0.07; TCGA PAAD -0.258; TCGA THCA -0.071 |
hsa-miR-101-3p | TNRC18 | 9 cancers: BLCA; CESC; ESCA; HNSC; LGG; LIHC; LUSC; PAAD; STAD | miRNATAP | TCGA BLCA -0.066; TCGA CESC -0.2; TCGA ESCA -0.187; TCGA HNSC -0.058; TCGA LGG -0.127; TCGA LIHC -0.152; TCGA LUSC -0.166; TCGA PAAD -0.377; TCGA STAD -0.199 |
hsa-miR-101-3p | KPNA3 | 9 cancers: BLCA; BRCA; CESC; ESCA; KIRC; OV; PRAD; THCA; STAD | miRNATAP | TCGA BLCA -0.382; TCGA BRCA -0.197; TCGA CESC -0.161; TCGA ESCA -0.229; TCGA KIRC -0.108; TCGA OV -0.161; TCGA PRAD -0.095; TCGA THCA -0.09; TCGA STAD -0.194 |
hsa-miR-101-3p | SLC25A3 | 10 cancers: BLCA; BRCA; CESC; COAD; KIRC; LGG; LIHC; LUAD; LUSC; PRAD | miRNATAP | TCGA BLCA -0.088; TCGA BRCA -0.105; TCGA CESC -0.065; TCGA COAD -0.17; TCGA KIRC -0.176; TCGA LGG -0.062; TCGA LIHC -0.105; TCGA LUAD -0.059; TCGA LUSC -0.085; TCGA PRAD -0.098 |
hsa-miR-101-3p | TOP1 | 10 cancers: BLCA; BRCA; CESC; ESCA; KIRC; LGG; OV; THCA; STAD; UCEC | miRNATAP | TCGA BLCA -0.075; TCGA BRCA -0.164; TCGA CESC -0.133; TCGA ESCA -0.185; TCGA KIRC -0.115; TCGA LGG -0.052; TCGA OV -0.055; TCGA THCA -0.125; TCGA STAD -0.143; TCGA UCEC -0.074 |
hsa-miR-101-3p | BZW1 | 15 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; KIRC; KIRP; LUAD; LUSC; OV; PAAD; PRAD; THCA; UCEC | miRNATAP | TCGA BLCA -0.178; TCGA BRCA -0.174; TCGA CESC -0.231; TCGA COAD -0.193; TCGA ESCA -0.262; TCGA HNSC -0.127; TCGA KIRC -0.152; TCGA KIRP -0.096; TCGA LUAD -0.079; TCGA LUSC -0.168; TCGA OV -0.164; TCGA PAAD -0.179; TCGA PRAD -0.126; TCGA THCA -0.08; TCGA UCEC -0.085 |
hsa-miR-101-3p | ZNF469 | 11 cancers: BLCA; CESC; ESCA; HNSC; LIHC; LUAD; LUSC; PAAD; SARC; THCA; STAD | miRNATAP | TCGA BLCA -0.77; TCGA CESC -0.246; TCGA ESCA -0.891; TCGA HNSC -0.388; TCGA LIHC -0.349; TCGA LUAD -0.105; TCGA LUSC -0.294; TCGA PAAD -0.619; TCGA SARC -0.315; TCGA THCA -0.419; TCGA STAD -0.454 |
hsa-miR-101-3p | VCAN | 11 cancers: BLCA; BRCA; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; SARC; THCA; UCEC | miRNATAP | TCGA BLCA -0.844; TCGA BRCA -0.378; TCGA ESCA -0.503; TCGA HNSC -0.211; TCGA KIRP -0.471; TCGA LGG -0.1; TCGA LIHC -0.684; TCGA LUAD -0.174; TCGA SARC -0.332; TCGA THCA -0.496; TCGA UCEC -0.315 |
hsa-miR-101-3p | SOX11 | 12 cancers: BLCA; BRCA; CESC; COAD; ESCA; HNSC; LGG; LIHC; LUSC; OV; PAAD; STAD | miRNATAP | TCGA BLCA -0.571; TCGA BRCA -0.846; TCGA CESC -1.117; TCGA COAD -0.532; TCGA ESCA -1.049; TCGA HNSC -0.872; TCGA LGG -0.416; TCGA LIHC -1.103; TCGA LUSC -0.712; TCGA OV -0.961; TCGA PAAD -1.171; TCGA STAD -0.733 |
hsa-miR-101-3p | AP1S3 | 9 cancers: BRCA; CESC; COAD; KIRC; KIRP; LIHC; PAAD; THCA; UCEC | miRNAWalker2 validate | TCGA BRCA -0.132; TCGA CESC -0.166; TCGA COAD -0.286; TCGA KIRC -0.221; TCGA KIRP -0.408; TCGA LIHC -0.275; TCGA PAAD -0.455; TCGA THCA -0.133; TCGA UCEC -0.412 |
hsa-miR-101-3p | CDC7 | 13 cancers: BRCA; COAD; ESCA; LGG; LIHC; LUAD; LUSC; OV; PRAD; SARC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.224; TCGA COAD -0.169; TCGA ESCA -0.218; TCGA LGG -0.13; TCGA LIHC -0.619; TCGA LUAD -0.099; TCGA LUSC -0.349; TCGA OV -0.184; TCGA PRAD -0.176; TCGA SARC -0.183; TCGA THCA -0.132; TCGA STAD -0.265; TCGA UCEC -0.193 |
hsa-miR-101-3p | E2F3 | 10 cancers: BRCA; CESC; ESCA; LGG; LIHC; LUAD; LUSC; THCA; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.178; TCGA CESC -0.132; TCGA ESCA -0.238; TCGA LGG -0.073; TCGA LIHC -0.408; TCGA LUAD -0.08; TCGA LUSC -0.25; TCGA THCA -0.053; TCGA STAD -0.202; TCGA UCEC -0.153 |
hsa-miR-101-3p | EZH2 | 10 cancers: BRCA; KIRP; LGG; LIHC; LUAD; LUSC; OV; PAAD; SARC; UCEC | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | TCGA BRCA -0.277; TCGA KIRP -0.343; TCGA LGG -0.384; TCGA LIHC -0.759; TCGA LUAD -0.179; TCGA LUSC -0.666; TCGA OV -0.193; TCGA PAAD -0.238; TCGA SARC -0.234; TCGA UCEC -0.315 |
hsa-miR-101-3p | MRPL42 | 9 cancers: BRCA; COAD; ESCA; KIRC; LGG; LIHC; LUAD; LUSC; STAD | miRNAWalker2 validate; MirTarget | TCGA BRCA -0.15; TCGA COAD -0.181; TCGA ESCA -0.171; TCGA KIRC -0.131; TCGA LGG -0.098; TCGA LIHC -0.052; TCGA LUAD -0.058; TCGA LUSC -0.206; TCGA STAD -0.124 |
hsa-miR-101-3p | MSH2 | 9 cancers: BRCA; CESC; ESCA; KIRC; LIHC; LUAD; LUSC; OV; STAD | miRNAWalker2 validate | TCGA BRCA -0.117; TCGA CESC -0.081; TCGA ESCA -0.179; TCGA KIRC -0.091; TCGA LIHC -0.37; TCGA LUAD -0.06; TCGA LUSC -0.255; TCGA OV -0.078; TCGA STAD -0.168 |
hsa-miR-101-3p | MTSS1L | 10 cancers: BRCA; COAD; ESCA; LGG; LUSC; PAAD; PRAD; SARC; THCA; STAD | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA BRCA -0.085; TCGA COAD -0.161; TCGA ESCA -0.263; TCGA LGG -0.059; TCGA LUSC -0.131; TCGA PAAD -0.297; TCGA PRAD -0.087; TCGA SARC -0.292; TCGA THCA -0.138; TCGA STAD -0.268 |
hsa-miR-101-3p | NOP2 | 11 cancers: BRCA; CESC; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.092; TCGA CESC -0.091; TCGA ESCA -0.201; TCGA HNSC -0.126; TCGA KIRP -0.204; TCGA LGG -0.114; TCGA LIHC -0.172; TCGA LUAD -0.111; TCGA LUSC -0.412; TCGA STAD -0.206; TCGA UCEC -0.088 |
hsa-miR-101-3p | RAC1 | 12 cancers: BRCA; ESCA; HNSC; KIRC; KIRP; LIHC; LUSC; PAAD; PRAD; THCA; STAD; UCEC | miRNAWalker2 validate; MirTarget | TCGA BRCA -0.14; TCGA ESCA -0.118; TCGA HNSC -0.087; TCGA KIRC -0.081; TCGA KIRP -0.14; TCGA LIHC -0.161; TCGA LUSC -0.12; TCGA PAAD -0.256; TCGA PRAD -0.091; TCGA THCA -0.054; TCGA STAD -0.123; TCGA UCEC -0.069 |
hsa-miR-101-3p | VEGFA | 10 cancers: BRCA; CESC; ESCA; HNSC; LGG; LUAD; LUSC; PAAD; STAD; UCEC | miRNAWalker2 validate | TCGA BRCA -0.245; TCGA CESC -0.44; TCGA ESCA -0.335; TCGA HNSC -0.281; TCGA LGG -0.179; TCGA LUAD -0.185; TCGA LUSC -0.202; TCGA PAAD -0.303; TCGA STAD -0.235; TCGA UCEC -0.131 |
hsa-miR-101-3p | MLEC | 9 cancers: BRCA; CESC; HNSC; LIHC; OV; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.065; TCGA CESC -0.187; TCGA HNSC -0.053; TCGA LIHC -0.198; TCGA OV -0.072; TCGA SARC -0.098; TCGA THCA -0.175; TCGA STAD -0.282; TCGA UCEC -0.115 |
hsa-miR-101-3p | RCN2 | 11 cancers: BRCA; CESC; COAD; ESCA; KIRC; LIHC; LUSC; OV; PRAD; SARC; STAD | MirTarget | TCGA BRCA -0.148; TCGA CESC -0.098; TCGA COAD -0.153; TCGA ESCA -0.165; TCGA KIRC -0.216; TCGA LIHC -0.244; TCGA LUSC -0.258; TCGA OV -0.166; TCGA PRAD -0.08; TCGA SARC -0.119; TCGA STAD -0.192 |
hsa-miR-101-3p | RAB15 | 9 cancers: BRCA; KIRC; LIHC; LUSC; OV; PAAD; SARC; THCA; UCEC | MirTarget | TCGA BRCA -0.082; TCGA KIRC -0.67; TCGA LIHC -0.279; TCGA LUSC -0.15; TCGA OV -0.168; TCGA PAAD -0.237; TCGA SARC -0.63; TCGA THCA -0.167; TCGA UCEC -0.145 |
hsa-miR-101-3p | SMARCA4 | 10 cancers: BRCA; CESC; ESCA; KIRC; LGG; LIHC; LUSC; PAAD; THCA; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.065; TCGA CESC -0.095; TCGA ESCA -0.131; TCGA KIRC -0.109; TCGA LGG -0.136; TCGA LIHC -0.313; TCGA LUSC -0.164; TCGA PAAD -0.159; TCGA THCA -0.093; TCGA UCEC -0.212 |
hsa-miR-101-3p | STX6 | 9 cancers: BRCA; ESCA; HNSC; LGG; LIHC; LUSC; PRAD; THCA; UCEC | MirTarget | TCGA BRCA -0.178; TCGA ESCA -0.262; TCGA HNSC -0.189; TCGA LGG -0.076; TCGA LIHC -0.335; TCGA LUSC -0.232; TCGA PRAD -0.061; TCGA THCA -0.07; TCGA UCEC -0.179 |
hsa-miR-101-3p | TMEM68 | 9 cancers: BRCA; ESCA; HNSC; KIRC; KIRP; LIHC; LUSC; OV; STAD | MirTarget | TCGA BRCA -0.087; TCGA ESCA -0.162; TCGA HNSC -0.074; TCGA KIRC -0.259; TCGA KIRP -0.089; TCGA LIHC -0.147; TCGA LUSC -0.16; TCGA OV -0.105; TCGA STAD -0.182 |
hsa-miR-101-3p | ZBED4 | 10 cancers: BRCA; CESC; ESCA; LGG; LIHC; LUSC; SARC; THCA; STAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.093; TCGA CESC -0.13; TCGA ESCA -0.164; TCGA LGG -0.089; TCGA LIHC -0.187; TCGA LUSC -0.179; TCGA SARC -0.187; TCGA THCA -0.1; TCGA STAD -0.152; TCGA UCEC -0.195 |
hsa-miR-101-3p | GDE1 | 9 cancers: BRCA; KIRC; KIRP; OV; PAAD; PRAD; THCA; STAD; UCEC | MirTarget | TCGA BRCA -0.097; TCGA KIRC -0.352; TCGA KIRP -0.113; TCGA OV -0.129; TCGA PAAD -0.232; TCGA PRAD -0.055; TCGA THCA -0.192; TCGA STAD -0.141; TCGA UCEC -0.166 |
hsa-miR-101-3p | CCNJ | 9 cancers: BRCA; CESC; KIRC; LGG; LIHC; LUAD; OV; STAD; UCEC | MirTarget; miRNATAP | TCGA BRCA -0.148; TCGA CESC -0.137; TCGA KIRC -0.16; TCGA LGG -0.123; TCGA LIHC -0.21; TCGA LUAD -0.094; TCGA OV -0.154; TCGA STAD -0.198; TCGA UCEC -0.197 |
hsa-miR-101-3p | IQGAP3 | 11 cancers: BRCA; CESC; ESCA; HNSC; LGG; LIHC; LUAD; LUSC; PAAD; SARC; UCEC | MirTarget | TCGA BRCA -0.431; TCGA CESC -0.152; TCGA ESCA -0.373; TCGA HNSC -0.118; TCGA LGG -0.325; TCGA LIHC -1.187; TCGA LUAD -0.199; TCGA LUSC -0.976; TCGA PAAD -0.727; TCGA SARC -0.423; TCGA UCEC -0.554 |
hsa-miR-101-3p | CENPO | 15 cancers: BRCA; CESC; ESCA; HNSC; KIRC; LGG; LIHC; LUAD; LUSC; OV; PAAD; SARC; THCA; STAD; UCEC | mirMAP | TCGA BRCA -0.282; TCGA CESC -0.155; TCGA ESCA -0.302; TCGA HNSC -0.179; TCGA KIRC -0.319; TCGA LGG -0.106; TCGA LIHC -0.485; TCGA LUAD -0.184; TCGA LUSC -0.443; TCGA OV -0.232; TCGA PAAD -0.198; TCGA SARC -0.243; TCGA THCA -0.15; TCGA STAD -0.176; TCGA UCEC -0.246 |
hsa-miR-101-3p | SIX4 | 9 cancers: BRCA; COAD; KIRC; LGG; LIHC; LUSC; PAAD; THCA; UCEC | miRNATAP | TCGA BRCA -0.149; TCGA COAD -0.51; TCGA KIRC -1.838; TCGA LGG -0.143; TCGA LIHC -0.897; TCGA LUSC -0.476; TCGA PAAD -0.999; TCGA THCA -0.314; TCGA UCEC -0.16 |
hsa-miR-101-3p | ONECUT2 | 9 cancers: BRCA; COAD; KIRC; KIRP; LGG; LUSC; SARC; THCA; UCEC | miRNATAP | TCGA BRCA -0.628; TCGA COAD -0.48; TCGA KIRC -1.602; TCGA KIRP -0.823; TCGA LGG -0.17; TCGA LUSC -0.761; TCGA SARC -0.334; TCGA THCA -0.192; TCGA UCEC -0.254 |
hsa-miR-101-3p | XPR1 | 10 cancers: BRCA; CESC; COAD; ESCA; HNSC; LIHC; LUSC; SARC; THCA; STAD | miRNATAP | TCGA BRCA -0.123; TCGA CESC -0.153; TCGA COAD -0.12; TCGA ESCA -0.45; TCGA HNSC -0.169; TCGA LIHC -0.176; TCGA LUSC -0.303; TCGA SARC -0.19; TCGA THCA -0.268; TCGA STAD -0.135 |
hsa-miR-101-3p | ANKRD52 | 11 cancers: BRCA; CESC; COAD; ESCA; KIRC; LIHC; LUAD; LUSC; SARC; THCA; STAD | miRNATAP | TCGA BRCA -0.062; TCGA CESC -0.183; TCGA COAD -0.116; TCGA ESCA -0.19; TCGA KIRC -0.168; TCGA LIHC -0.498; TCGA LUAD -0.106; TCGA LUSC -0.161; TCGA SARC -0.139; TCGA THCA -0.114; TCGA STAD -0.263 |
hsa-miR-101-3p | HAPLN1 | 12 cancers: BRCA; CESC; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; SARC; THCA; UCEC | miRNATAP | TCGA BRCA -0.855; TCGA CESC -0.778; TCGA HNSC -0.672; TCGA KIRP -0.526; TCGA LGG -0.24; TCGA LIHC -0.749; TCGA LUAD -0.342; TCGA LUSC -0.337; TCGA PAAD -1.153; TCGA SARC -0.817; TCGA THCA -0.352; TCGA UCEC -0.623 |
hsa-miR-101-3p | NANOS1 | 10 cancers: BRCA; HNSC; KIRC; KIRP; LGG; LIHC; LUSC; OV; PRAD; STAD | miRNATAP | TCGA BRCA -0.144; TCGA HNSC -0.108; TCGA KIRC -0.258; TCGA KIRP -0.123; TCGA LGG -0.06; TCGA LIHC -0.183; TCGA LUSC -0.121; TCGA OV -0.239; TCGA PRAD -0.095; TCGA STAD -0.244 |
hsa-miR-101-3p | AMMECR1 | 10 cancers: BRCA; ESCA; HNSC; KIRC; LIHC; LUSC; OV; SARC; THCA; UCEC | miRNATAP | TCGA BRCA -0.174; TCGA ESCA -0.418; TCGA HNSC -0.136; TCGA KIRC -0.25; TCGA LIHC -0.11; TCGA LUSC -0.291; TCGA OV -0.123; TCGA SARC -0.147; TCGA THCA -0.064; TCGA UCEC -0.158 |
hsa-miR-101-3p | TEAD3 | 9 cancers: BRCA; ESCA; KIRC; LIHC; LUSC; PAAD; PRAD; SARC; STAD | miRNATAP | TCGA BRCA -0.061; TCGA ESCA -0.235; TCGA KIRC -0.176; TCGA LIHC -0.183; TCGA LUSC -0.233; TCGA PAAD -0.546; TCGA PRAD -0.064; TCGA SARC -0.346; TCGA STAD -0.263 |
hsa-miR-101-3p | NACC1 | 15 cancers: BRCA; CESC; COAD; ESCA; HNSC; KIRC; LIHC; LUAD; LUSC; PAAD; PRAD; SARC; THCA; STAD; UCEC | miRNATAP | TCGA BRCA -0.099; TCGA CESC -0.193; TCGA COAD -0.154; TCGA ESCA -0.227; TCGA HNSC -0.157; TCGA KIRC -0.153; TCGA LIHC -0.209; TCGA LUAD -0.094; TCGA LUSC -0.287; TCGA PAAD -0.288; TCGA PRAD -0.124; TCGA SARC -0.13; TCGA THCA -0.173; TCGA STAD -0.202; TCGA UCEC -0.179 |
hsa-miR-101-3p | NDRG4 | 10 cancers: BRCA; COAD; ESCA; HNSC; KIRC; KIRP; LIHC; LUAD; OV; THCA | miRNATAP | TCGA BRCA -0.144; TCGA COAD -0.297; TCGA ESCA -0.578; TCGA HNSC -0.274; TCGA KIRC -0.442; TCGA KIRP -0.507; TCGA LIHC -0.276; TCGA LUAD -0.277; TCGA OV -0.211; TCGA THCA -0.249 |
hsa-miR-101-3p | E2F8 | 9 cancers: BRCA; LGG; LIHC; LUAD; LUSC; PRAD; SARC; THCA; UCEC | miRNATAP | TCGA BRCA -0.492; TCGA LGG -0.475; TCGA LIHC -0.924; TCGA LUAD -0.166; TCGA LUSC -0.745; TCGA PRAD -0.238; TCGA SARC -0.363; TCGA THCA -0.29; TCGA UCEC -0.428 |
hsa-miR-101-3p | SMARCD1 | 9 cancers: CESC; ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; UCEC | miRNAWalker2 validate; MirTarget; miRNATAP | TCGA CESC -0.071; TCGA ESCA -0.159; TCGA HNSC -0.08; TCGA KIRP -0.112; TCGA LGG -0.121; TCGA LIHC -0.271; TCGA LUAD -0.076; TCGA LUSC -0.191; TCGA UCEC -0.06 |
hsa-miR-101-3p | LRRC14 | 10 cancers: CESC; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; SARC; STAD | mirMAP | TCGA CESC -0.07; TCGA HNSC -0.082; TCGA KIRP -0.108; TCGA LGG -0.092; TCGA LIHC -0.335; TCGA LUAD -0.076; TCGA LUSC -0.206; TCGA PAAD -0.149; TCGA SARC -0.109; TCGA STAD -0.162 |
hsa-miR-101-3p | CA12 | 12 cancers: COAD; ESCA; HNSC; KIRC; LGG; LIHC; LUSC; PAAD; SARC; THCA; STAD; UCEC | mirMAP | TCGA COAD -0.377; TCGA ESCA -0.924; TCGA HNSC -0.321; TCGA KIRC -0.351; TCGA LGG -0.215; TCGA LIHC -1.219; TCGA LUSC -0.889; TCGA PAAD -0.95; TCGA SARC -0.728; TCGA THCA -0.343; TCGA STAD -0.452; TCGA UCEC -0.423 |
hsa-miR-101-3p | GMEB2 | 9 cancers: ESCA; HNSC; KIRP; LGG; LIHC; LUAD; LUSC; PAAD; STAD | miRNAWalker2 validate | TCGA ESCA -0.128; TCGA HNSC -0.076; TCGA KIRP -0.082; TCGA LGG -0.053; TCGA LIHC -0.15; TCGA LUAD -0.111; TCGA LUSC -0.2; TCGA PAAD -0.173; TCGA STAD -0.139 |
Enriched cancer pathways of putative targets